Navigation Links
HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
Date:6/16/2011

FRAMINGHAM, Mass. and SYDNEY, June 16, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Wells Fargo 2011 Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, June 22, 2011.  The conference is being held June 22-23, 2011 at The InterContinental Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian S
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
(Date:7/14/2014)... Tysons, VA (PRWEB) July 14, 2014 ... been a local icon to the Tysons Corner skyline ... Corner becoming its own municipality, known simply as “Tysons”, ... Sheraton Tysons Hotel. In addition to Tysons becoming ... Stations located in the heart of Tysons brings an ...
(Date:7/14/2014)... TX (PRWEB) July 14, 2014 Kenn Renner ... recently. The video is meant to describe the business on ... estate broker and national speaker – Kenn Renner – is ... branding, marketing, and goal setting techniques. , Investing in real ... money. Some people do it as their career, while others ...
(Date:7/14/2014)... 2014 Dry eyes, contrary to popular opinion, ... recent research have pointed out, today’s technology has practically enabled ... as a result of using laptops and smartphones to ... Because of this phenomenon, it has become imperative for people ... cure them from having dry eyes, but prevent it from ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 The Cabin ... launched its new Alumni Community website – ... treatment, to help them maintain lifelong recovery wherever they ... that providing clients the tools to help them maintain ... and essential part of any reputable treatment programme. As ...
(Date:7/14/2014)... July 14, 2014 EurekaMag.com has newly ... which is a contagious liver disease that ranges ... weeks to a serious, lifelong illness that attacks the ... States have chronic Hepatitis C virus infection of which ... site's research category covers all studies on Hepatitis ...
Breaking Medicine News(10 mins):Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 2Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 3Health News:Iconic Tyson’s Corner Hotel Embraces the New “Tysons” Evolution 4Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2
... off from certain osteoporosis drugs may be beneficial to bone ... System. Researchers found that bone density remained stable for three ... a popular class of osteoporosis drugs that can cause fractures ... bone. "These drugs are potentially harmful when taken for ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Nov. ... evidence that people infected with HIV, the virus that causes ... other patients when they undergo kidney transplants. Up until ... HIV patients because of fear that AIDS would quickly kill ...
... Johns Hopkins have identified a compound that could be ... The compound, called a glutaminase inhibitor, has been ... scientists say, may have the potential to be used ... Johns Hopkins scientists, are inventors on patent applications related ...
... NC Researchers have been stymied for years over the ... produce antibodies in response to the pathogen antibodies that ... at Duke University Medical Center can explain why: Some of ... can,t actually "see" the virus until after it,s already invaded ...
... THURSDAY, Nov. 18 (HealthDay News) -- Millions of harried ... indoor smoking at one in every four major U.S. ... smoke-free policies at large-hub airports in 2002 and 2010 ... nation,s largest airports, including three of the five busiest: ...
... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay ... example, new research finds that doctors, prescribing patterns vary across ... U.S. Food and Drug Administration. The result is ... depending on where they live, the researchers said. "We ...
Cached Medicine News:Health News:Taking a break from osteoporosis drugs can protect bones 2Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:Compound that blocks sugar pathway slows cancer cell growth 2Health News:Compound that blocks sugar pathway slows cancer cell growth 3Health News:Why so many antibodies fail to protect against HIV infection 2Health News:Smoking Still Allowed at 1 in 4 Major U.S. Airports 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: